HR 1266 Passed House Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Combating Illicit Xylazine Act
Summary
- Defines "xylazine" in the Controlled Substances Act to include the substance, its salts, and isomers.
- Places xylazine in Schedule III of the Controlled Substances Act, with an exception for drug products approved under the Federal Food, Drug, and Cosmetic Act.
- Redefines "ultimate user" for xylazine to cover people who receive it from a registered veterinarian or a pharmacy filling a veterinarian's prescription, and who possess it for animals, animal-control or wildlife programs, or similar uses.
- Delays the Schedule III labeling and packaging requirements for xylazine by one year and the practitioner registration, inventory, and recordkeeping requirements by 60 days after enactment.
- Adds xylazine to the Automation of Reports and Consolidated Orders System (ARCOS) tracking requirements.
- Directs the U.S. Sentencing Commission to review and, if appropriate, amend sentencing guidelines for xylazine offenses.
- Requires the Attorney General, through the DEA and in coordination with the FDA, to report to Congress on illicit xylazine use within 18 months of enactment and again within 4 years.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
-
Rep. Panetta, Jimmy (D-CA) [#19]
112 cosponsors
-
Rep. Alford, Mark (R-MO) [#4] -
Rep. Auchincloss, Jake (D-MA) [#4] -
Rep. Bacon, Don (R-NE) [#2] -
Rep. Baird, James R. (R-IN) [#4] -
Rep. Balderson, Troy (R-OH) [#12] -
Rep. Barragán, Nanette Diaz (D-CA) [#44] -
Rep. Bentz, Cliff (R-OR) [#2] -
Rep. Bergman, Jack (R-MI) [#1] -
Rep. Bice, Stephanie I. (R-OK) [#5] -
Rep. Biggs, Sheri (R-SC) [#3] -
Rep. Bilirakis, Gus M. (R-FL) [#12] -
Rep. Budzinski, Nikki (D-IL) [#13] -
Rep. Burchett, Tim (R-TN) [#2] -
Rep. Calvert, Ken (R-CA) [#41] -
Rep. Carey, Mike (R-OH) [#15] -
Rep. Carter, Earl L. "Buddy" (R-GA) [#1] -
Rep. Cherfilus-McCormick, Sheila (D-FL) [#20] -
Rep. Ciscomani, Juan (R-AZ) [#6] -
Rep. Clarke, Yvette D. (D-NY) [#9] -
Rep. Cohen, Steve (D-TN) [#9] -
Rep. Collins, Mike (R-GA) [#10] -
Rep. Correa, J. Luis (D-CA) [#46] -
Rep. Costa, Jim (D-CA) [#21] -
Rep. Craig, Angie (D-MN) [#2] -
Rep. Crenshaw, Dan (R-TX) [#2] -
Rep. Davids, Sharice (D-KS) [#3] -
Rep. Davis, Donald G. (D-NC) [#1] -
Rep. Dean, Madeleine (D-PA) [#4] -
Rep. De La Cruz, Monica (R-TX) [#15] -
Rep. DelBene, Suzan K. (D-WA) [#1] -
Rep. Deluzio, Christopher R. (D-PA) [#17] -
Rep. DesJarlais, Scott (R-TN) [#4] -
Rep. Edwards, Chuck (R-NC) [#11] -
Rep. Evans, Gabe (R-CO) [#8] -
Rep. Finstad, Brad (R-MN) [#1] -
Rep. Fischbach, Michelle (R-MN) [#7] -
Rep. Fitzgerald, Scott (R-WI) [#5] -
Rep. Fitzpatrick, Brian K. (R-PA) [#1] -
Rep. Fong, Vince (R-CA) [#20] -
Rep. Foushee, Valerie P. (D-NC) [#4] -
Rep. Garamendi, John (D-CA) [#8] -
Rep. Gillen, Laura (D-NY) [#4] -
Rep. Goldman, Craig A. (R-TX) [#12] -
Rep. Gottheimer, Josh (D-NJ) [#5] -
Rep. Gray, Adam (D-CA) [#13] -
Rep. Grothman, Glenn (R-WI) [#6] -
Rep. Harder, Josh (D-CA) [#9] -
Rep. Haridopolos, Mike (R-FL) [#8] -
Rep. Harris, Andy (R-MD) [#1] -
Rep. Harshbarger, Diana (R-TN) [#1] -
Rep. Ivey, Glenn (D-MD) [#4] -
Rep. Jackson, Ronny (R-TX) [#13] -
Rep. Johnson, Dusty (R-SD) [At-large] -
Rep. Joyce, John (R-PA) [#13] -
Rep. Kelly, Robin L. (D-IL) [#2] -
Rep. Kennedy, Timothy M. (D-NY) [#26] -
Rep. Kim, Young (R-CA) [#40] -
Rep. Knott, Brad (R-NC) [#13] -
Rep. Langworthy, Nicholas A. (R-NY) [#23] -
Rep. Lee, Laurel M. (R-FL) [#15] -
Rep. Letlow, Julia (R-LA) [#5] -
Rep. Lofgren, Zoe (D-CA) [#18] -
Rep. Lucas, Frank D. (R-OK) [#3] -
Rep. Mackenzie, Ryan (R-PA) [#7] -
Rep. Magaziner, Seth (D-RI) [#2] -
Rep. Mann, Tracey (R-KS) [#1] -
Rep. McBride, Sarah (D-DE) [At-large] -
Rep. McDonald Rivet, Kristen (D-MI) [#8] -
Rep. McDowell, Addison (R-NC) [#6] -
Rep. Miller-Meeks, Mariannette (R-IA) [#1] -
Rep. Min, Dave (D-CA) [#47] -
Rep. Moore, Tim (R-NC) [#14] -
Rep. Nehls, Troy E. (R-TX) [#22] -
Rep. Norcross, Donald (D-NJ) [#1] -
Rep. Nunn, Zachary (R-IA) [#3] -
Rep. Obernolte, Jay (R-CA) [#23] -
Rep. Pappas, Chris (D-NH) [#1] -
Rep. Perez, Marie Gluesenkamp (D-WA) [#3] -
Rep. Peters, Scott H. (D-CA) [#50] -
Rep. Pettersen, Brittany (D-CO) [#7] -
Rep. Pfluger, August (R-TX) [#11] -
Rep. Riley, Josh (D-NY) [#19] -
Rep. Ross, Deborah K. (D-NC) [#2] -
Rep. Rouzer, David (R-NC) [#7] -
Rep. Rulli, Michael A. (R-OH) [#6] -
Rep. Salinas, Andrea (D-OR) [#6] -
Rep. Schmidt, Derek (R-KS) [#2] -
Rep. Scholten, Hillary J. (D-MI) [#3] -
Rep. Schrier, Kim (D-WA) [#8] -
Rep. Self, Keith (R-TX) [#3] -
Rep. Sewell, Terri A. (D-AL) [#7] -
Rep. Simpson, Michael K. (R-ID) [#2] -
Rep. Smith, Christopher H. (R-NJ) [#4] -
Rep. Sorensen, Eric (D-IL) [#17] -
Rep. Soto, Darren (D-FL) [#9] -
Rep. Steil, Bryan (R-WI) [#1] -
Rep. Suozzi, Thomas R. (D-NY) [#3] -
Rep. Tenney, Claudia (R-NY) [#24] -
Rep. Thompson, Mike (D-CA) [#4] -
Rep. Titus, Dina (D-NV) [#1] -
Rep. Tokuda, Jill N. (D-HI) [#2] -
Rep. Trahan, Lori (D-MA) [#3] -
Rep. Van Drew, Jefferson (R-NJ) [#2] -
Rep. Van Duyne, Beth (R-TX) [#24] -
Rep. Van Orden, Derrick (R-WI) [#3] -
Rep. Vasquez, Gabe (D-NM) [#2] -
Rep. Vindman, Eugene (D-VA) [#7] -
Rep. Weber, Randy K. Sr. (R-TX) [#14] -
Rep. Webster, Daniel (R-FL) [#11] -
Rep. Wittman, Robert J. (R-VA) [#1] -
Rep. Yakym, Rudy (R-IN) [#2] -
Rescom. Hernández, Pablo Jose (D-PR) [At-large]
Actions (18)
- Sep 16, 2026 Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623. · senate
- Sep 15, 2026 Motion to reconsider laid on the table Agreed to without objection. · house
- Sep 15, 2026 On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672) · house
- Sep 15, 2026 Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Sep 15, 2026 DEBATE - The House proceeded with forty minutes of debate on H.R. 1266. · house
- Sep 15, 2026 Considered under suspension of the rules. (consideration: CR H5671-5673) · house
- Sep 15, 2026 Mr. Guthrie moved to suspend the rules and pass the bill, as amended. · house
- Sep 14, 2026 Placed on the Union Calendar, Calendar No. 715. · house
- Sep 14, 2026 Committee on the Judiciary discharged. · house
- Sep 14, 2026 Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-816, Part I. · house
- Jul 21, 2026 Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0. · house
- Jul 21, 2026 Committee Consideration and Mark-up Session Held · house
- Jul 20, 2026 Committee Consideration and Mark-up Session Held · house
- Jun 25, 2026 Forwarded by Subcommittee to Full Committee by Voice Vote. · house
- Jun 25, 2026 Subcommittee Consideration and Mark-up Session Held · house
- Feb 12, 2025 Referred to the Subcommittee on Health. · house
- Feb 12, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
- Feb 12, 2025 Introduced in House
Committee action (4)
What happened to this bill in committee — the meetings where it was considered and every recorded vote taken on it.
Meetings where this bill was on the agenda
Full text
AN ACT
To prohibit certain uses of xylazine, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Combating Illicit Xylazine Act”.
SEC. 2. DEFINITIONS.
(a) In General.—In this Act, the term “xylazine” has the meaning given the term in paragraph (61) of section 102 of the Controlled Substances Act, as added by subsection (b) of this section.
(b) Controlled Substances Act.—Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended by adding at the end the following:
“(61) The term ‘xylazine’ means the substance xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible.”.
SEC. 3. ADDING XYLAZINE TO SCHEDULE III.
Schedule III of section 202(c) of the Controlled Substances Act (21 U.S.C. 812) is amended by adding at the end the following:
“(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of xylazine.”.
SEC. 4. AMENDMENTS.
(a) Amendment.—Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended by striking paragraph (27) and inserting the following:
“(27)(A) Except as provided in subparagraph (B), the term ‘ultimate user’ means a person who has lawfully obtained, and who possesses, a controlled substance for the use by the person or for the use of a member of the household of the person or for an animal owned by the person or by a member of the household of the person.
“(B)(i) In the case of xylazine, other than for a drug product approved under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), the term ‘ultimate user’ means a person—
“(I) to whom xylazine was dispensed by— “(aa) a veterinarian registered under this Act; or “(bb) a pharmacy registered under this Act pursuant to a prescription of a veterinarian registered under this Act; and
“(II) who possesses xylazine for— “(aa) an animal owned by the person or by a member of the household of the person; “(bb) an animal under the care of the person;
“(cc) use in government animal-control programs authorized under applicable Federal, State, Tribal, or local law; or
“(dd) use in wildlife programs authorized under applicable Federal, State, Tribal, or local law.
“(ii) In this subparagraph, the term ‘person’ includes—
“(I) a government agency or business where animals are located; and
“(II) an employee or agent of an agency or business acting within the scope of their employment or agency.”.
(b) Facilities.—An entity that manufactures xylazine, as of the date of enactment of this Act, shall not be required to make capital expenditures necessary to install the security standard required of schedule III of the Controlled Substances Act (21 U.S.C. 801 et seq.) for the purposes of manufacturing xylazine.
(c) Labeling.—The requirements related to labeling, packaging, and distribution logistics of a controlled substance in schedule III of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) shall not take effect for xylazine until the date that is 1 year after the date of enactment of this Act.
(d) Practitioner Registration.—The requirements related to practitioner registration, inventory, and recordkeeping of a controlled substance in schedule III of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) shall not take effect for xylazine until the date that is 60 days after the date of enactment of this Act. A practitioner that has applied for registration during the 60-day period beginning on the date of enactment of this Act may continue their lawful activities until such application is approved or denied.
(e) Manufacturer Transition.—The Food and Drug Administration and the Drug Enforcement Administration shall facilitate and expedite the relevant manufacturer submissions or applications required by the placement of xylazine on schedule III of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)).
(f) Clarification.—Nothing in this Act, or the amendments made by this Act, shall be construed to require the registration of an ultimate user of xylazine under the Controlled Substances Act (21 U.S.C. 801 et seq.) in order to possess xylazine in accordance with subparagraph (B) of section 102(27) of that Act (21 U.S.C. 802(27)), as added by subsection (a) of this section.
SEC. 5. ARCOS TRACKING.
Section 307(i) of the Controlled Substances Act (21 U.S.C. 827(i)) is amended—
(1) in the matter preceding paragraph (1)—
(A) by inserting “or xylazine” after “gamma hydroxybutyric acid”;
(B) by inserting “or 512” after “section 505”; and
(C) by inserting “respectively,” after “the Federal Food, Drug, and Cosmetic Act,”; and
(2) in paragraph (6), by inserting “or xylazine” after “gamma hydroxybutyric acid”.
SEC. 6. SENTENCING COMMISSION.
Pursuant to its authority under section 994(p) of title 28, United States Code, the United States Sentencing Commission shall review and, if appropriate, amend its sentencing guidelines, policy statements, and official commentary applicable to persons convicted of an offense under section 401 of the Controlled Substances Act (21 U.S.C. 841) or section 1010 of the Controlled Substances Import and Export Act (21 U.S.C. 960) to provide appropriate penalties for offenses involving xylazine that are consistent with the amendments made by this Act. In carrying out this section, the Commission should consider the common forms of xylazine as well as its use alongside other scheduled substances.
SEC. 7. REPORT TO CONGRESS ON XYLAZINE.
(a) Initial Report.—Not later than 18 months after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report on the prevalence of illicit use of xylazine in the United States and the impacts of such use, including—
(1) where the drug is being diverted;
(2) where the drug is originating; and
(3) whether any analogues to xylazine, or related or derivative substances, exist and present a substantial risk of abuse.
(b) Additional Report.—Not later than 4 years after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report updating Congress on the prevalence and proliferation of xylazine trafficking and misuse in the United States.
Passed the House of Representatives September 15, 2026.
Attest:
Clerk. 119th CONGRESS
2d Session
H. R. 1266
AN ACT
To prohibit certain uses of xylazine, and for other purposes.
Text versions (4)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
More bills on these subjects (8)
Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).
Comments